NCT04407507View on ClinicalTrials.gov

Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

January 29, 2021

Study Completion Date

January 29, 2021

Conditions
COVID-19
Interventions
DRUG

Ivermectin

ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days

DRUG

Placebo

Placebo of ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days

Trial Locations (1)

Unknown

Investigacion Biomédica para el Desarrollo de Fármacos S.A. de C.V., Zapopan

All Listed Sponsors
lead

Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.

OTHER

NCT04407507 - Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms | Biotech Hunter | Biotech Hunter